The Company had approximately $98.8 million in cash and cash equivalents as of December 31, 2024. Net cash used in operating activities was approximately $60.9 million, compared to $102.0 million ...
Aurora Pharmaceutical logo "Our sales team is the backbone of our customer relationships, and this expansion reflects both our business growth and our dedication to providing best-in-class service to ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Rua Dr. Diogo de Faria, 1087 – 9º andar – Vila Clementino 04037-003 São Paulo/SP - Brasil E-mail: [email protected] ...
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its cystic fibrosis drugs and early contributions from a newly approved non ...
NORTHFIELD, Minn., Jan. 28, 2025 /PRNewswire/ -- Aurora Pharmaceutical, a leading manufacturer of animal health products, is excited to announce the appointment of Stephanie Hastings as its new ...
NORTHFIELD, Minn., Jan. 28, 2025 /PRNewswire/ -- Aurora Pharmaceutical, a leading manufacturer of animal health products, is excited to announce the appointment of Stephanie Hastings as its new ...
Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $28.00. The company’s shares closed yesterday at $21.78.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results